Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pneumococcal 20-valent conjugate vaccine (Pfizer, f29485)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pneumococcal 20-valent conjugate vaccine (PCV20) is a sterile suspension of saccharides of the capsular antigens of 20 serotypes of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) individually conjugated to a non-toxic diphtheria cross-reactive material 197 (CRM197) carrier protein. Developed by Pfizer, the vaccine is designed to provide active immunization for the prevention of invasive disease and pneumonia caused by these 20 serotypes in individuals 6 weeks of age and older, as well as otitis media in infants and young children. It builds upon the 13-valent vaccine (Prevnar 13) by adding seven additional serotypes associated with high case-fatality rates, antibiotic resistance, and meningitis.
- Brand names
- ApexxnarPrevenar 20Prevenar20Prevenar-20Prevnar 20Prevnar20Prevnar-20
- Other names
- Pneu-C-20Pneu-C20Pneu-C 20pneumococcal conjugate vaccine (20-valent)pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD40 (Cluster of differentiation 40 receptor)MHC II (Major histocompatibility complex class II receptor)SpCPS1 (Streptococcus pneumoniae capsular polysaccharide serotype 1)10A CPS (Streptococcus pneumoniae serotype 10A capsular polysaccharide)11A CPS (Streptococcus pneumoniae serotype 11A capsular polysaccharide)12F CPS (Streptococcus pneumoniae serotype 12F capsular polysaccharide)CPS14 (Streptococcus pneumoniae capsular polysaccharide serotype 14)15B CPS (Streptococcus pneumoniae serotype 15B capsular polysaccharide)CPS 18C (Streptococcus pneumoniae capsular polysaccharide serotype 18C)19A CPS (Streptococcus pneumoniae serotype 19A capsular polysaccharide)CPS19F (Streptococcus pneumoniae capsular polysaccharide serotype 19F)CPS 22F (Streptococcus pneumoniae serotype 22F capsular polysaccharide)CPS23F (Streptococcus pneumoniae capsular polysaccharide serotype 23F)PPS3 (Streptococcus pneumoniae serotype 3 capsular polysaccharide)33F CPS (Streptococcus pneumoniae serotype 33F capsular polysaccharide)CPS4 (Streptococcus pneumoniae capsular polysaccharide serotype 4)PPS5 (Streptococcus pneumoniae capsular polysaccharide serotype 5)6A CPS (Streptococcus pneumoniae serotype 6A capsular polysaccharide)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)7F CPS (Streptococcus pneumoniae serotype 7F capsular polysaccharide)Streptococcus pneumoniae capsular polysaccharide serotype 9V (PnPS 9V)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on pneumococcal 20-valent conjugate vaccine (Pfizer, f29485).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pneumococcal 20-valent conjugate vaccine (Pfizer, f29485).